| Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease (NCT04534985) | University of Colorado, Denver | 2021-02-09 |
| PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) (NCT04407481) | University of Colorado, Denver | 2020-11-01 |
| Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt (NCT04310319) | Esther Meijer | 2020-09-07 |
| Effect of Venglustat in Patients With Renal Impairment (NCT03687554) | Genzyme, a Sanofi Company | 2018-10-05 |
| A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (NCT03523728) | Genzyme, a Sanofi Company | 2018-10-04 |
| Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease (NCT03342742) | University of Colorado, Denver | 2018-06-04 |
| The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease (NCT04363554) | Regional Hospital Holstebro | 2017-09-25 |
| Feasibility Study of Metformin Therapy in ADPKD (NCT02903511) | University of Colorado, Denver | 2016-11-01 |
| Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (NCT02656017) | Kyongtae Ty Bae, M.D., Ph.D. | 2016-06-27 |
| Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD (NCT03803124) | Regional Hospital Holstebro | 2015-12-01 |
| Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD (NCT02494141) | University of Colorado, Denver | 2015-11-12 |
| Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (NCT02251275) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-10-17 |
| Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD (NCT02847624) | Otsuka Pharmaceutical Co., Ltd. | 2014-03-24 |
| A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (NCT01559363) | Kadmon, a Sanofi Company | 2012-10-11 |
| The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease (NCT01589705) | TC Erciyes University | 2012-01-01 |
| The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease (NCT04023214) | Sheffield Teaching Hospitals NHS Foundation Trust | 2011-07-25 |
| Bosutinib For Autosomal Dominant Polycystic Kidney Disease (NCT01233869) | Pfizer | 2010-12-01 |
| Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease (NCT01114594) | The Rogosin Institute | 2010-04-01 |
| Lanreotide as Treatment of Polycystic Livers (NCT00565097) | Radboud University Medical Center | 2007-10-01 |
| Octreotide in Severe Polycystic Liver Disease (NCT00426153) | Mayo Clinic | 2007-01-01 |
| Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NCT00456365) | University of Colorado, Denver | 2006-11-01 |
| The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease (NCT00410007) | Carolina Cannillo | 2006-10-01 |
| Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NCT00413777) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2005-12-01 |